Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) released its 2024 financial report, recording RMB...
Finanical Reports
Akeso Biopharma Reports 53% Revenue Decline in 2024 Despite Growth in Product Sales
China-based Akeso Biopharma (HKG: 9926) released its 2024 financial report, recording RMB 2.124 billion (USD...
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues...
Shanghai Pharmaceuticals Reports 5.75% Revenue Growth in 2024 with Innovation Initiatives
China’s Shanghai Pharmaceuticals (SPH; SHA: 601607, HKG: 2607) released its 2024 financial results, showing total...
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362...
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257...
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial...
WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024...
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results....
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with...
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...
Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales
Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...